Lung Cancer

Lung Cancer Treatment

Taussig Cancer Institute's Thoracic Oncology Program offers patients with thoracic malignancies leading-edge, multidisciplinary care. In consultation with patients, collaborative teams of surgical, medical, and radiation oncologists tailor treatment plans to the needs of each patient. An active clinical research program provides patients with additional treatment options.

The Department of Radiation Oncology actively participates in Cleveland Clinic in-house protocols and is a full member of the NRG Oncology research organization. The department is among the leading institutions nationally for accrual of patients to multiple NRG Oncology clinical trials.

Five-Year Overall Survival of Patients With All Stagesᵃ of Non-Small Cell Lung Cancer (N= 7128)

2009-2019

ᵃAJCC stage I-IV small cell lung cancer

ᵇHowlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER website, April 2016.

Five-Year Overall Survival of Patients With Non-Small Cell Lung Cancer by Stageᵃ (N = 6646)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage I (N = 2099)17921310912604354
Stage II (N = 697)561395264180104
Stage III (N = 1318)865513333219114
Stage IV (N = 2327)92643923013459

ᵃAJCC stage I-IV non-small cell lung cancer

ᵇHowlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER website, April 2016. The national comparison is the 5-year overall survival of patients with all stages of non-small cell cancer from 2006-2012.

Overall Survival of Patients With Medically Inoperable Stage Iᵃ Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy (N = 1055)

2006-2016

ᵃAJCC stage I non-small cell lung cancer

ᵇThere is no reference value for year 4

ᶜZheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-611

Local Control for Patients With Medically Inoperable Stage Iᵃ Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy (N = 1055)

2006-2016

CC = Cleveland Clinic

ᵃAJCC stage I non-small cell lung cancer

ᵇThere is no reference value for years 2 and 4

ᶜZheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):603-611.

Five-Year Overall Survival of Patients With Stage IIIᵃ Non-Small Cell Lung Cancer Treated With Radiation (N= 855)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage IIIA (N = 586)39425816710455
Stage IIIB (N = 269)16582523017

ᵃAJCC stage III non-small cell lung cancer

Five-Year Overall Survival of Patients With All Stages of Small Cell Lung Cancerᵃ (N= 837)

2009-2019

ᵃAmerican Joint Committee on Cancer (AJCC) stage I-IV non-small cell lung cancer

ᵇ Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER website, April 2016.

Five-Year Overall Survival of Patients With Early Stageᵃ Small Cell Lung Cancer (N = 330)

2009-2019

Number at RiskYear 1Year 2Year 3Year 4Year 5
Stage I (N = 70)553829219
Stage II (N = 59)382215107
Stage III (N = 201)11568483421

ᵃAJCC stage I-III small cell lung cancer